US · NOTV
Inotiv, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- West Lafayette, IN 47906-1382
- Website
- inotivco.com
Price · as of 2025-09-30
$0.31
Market cap 9.31M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $14.36 | +4,532.26% |
| Intrinsic Value(DCF) | $0.32 | +3.23% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $1.50 | $183.11 | $0.28 | $2.10 | $2.17 |
| 2012 | $1.20 | $380.15 | $0.00 | $0.00 | $5.38 |
| 2013 | $2.30 | $1,481.63 | $0.29 | $1.40 | $0.00 |
| 2014 | $2.25 | $59.72 | $0.13 | $0.31 | $0.00 |
| 2015 | $1.55 | $73.09 | $0.21 | $1.88 | $0.12 |
| 2016 | $0.95 | $161.77 | $0.04 | $0.00 | $0.57 |
| 2017 | $2.81 | $55.73 | $0.44 | $1.57 | $2.80 |
| 2018 | $1.31 | $58.38 | $0.72 | $0.78 | $0.00 |
| 2019 | $4.48 | $80.53 | $288.62 | $0.30 | $0.00 |
| 2020 | $7.20 | $67.40 | $564.50 | $0.00 | $0.00 |
| 2021 | $48.28 | $70.67 | $1,524.54 | $8.16 | $44.80 |
| 2022 | $5.68 | $326.18 | $58,794.75 | $0.00 | $0.00 |
| 2023 | $3.38 | $357.58 | $682.53 | $0.00 | $0.00 |
| 2024 | $3.80 | $43.62 | $78.03 | $0.00 | $22.83 |
| 2025 | $0.81 | $14.36 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Inotiv, Inc.'s (NOTV) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $14.36
- Current price
- $0.31
- AI upside
- +4,532.26%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.32
+3.23% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NOTV | Inotiv, Inc. | $0.31 | 9.31M | +4,532% | +3% | — | — | -0.38 | 0.19 | 0.05 | 20.53 | — | -0.13 | 12.68% | -6.02% | -13.38% | -44.78% | -3.99% | -8.84% | 3.70 | -0.55 | 0.35 | 0.21 | 19.47 | -4964.00% | 454.00% | -702.00% | -102.98% | -0.02 | -4.47% | 0.00% | 0.00% | 0.00% | -16.44 | -18.77 | 0.99 | -1.15 |
| BDSX | Biodesix, Inc. | $15.33 | 121.96M | +481% | +136% | — | — | -3.37 | -48.25 | 1.34 | -7.90 | — | -5.56 | 75.25% | -31.50% | -39.85% | -383.09% | -51.61% | -38.18% | -29.56 | -3.61 | 1.86 | 1.61 | -2.46 | -2924.00% | 2408.00% | -5464.00% | -19.79% | -1.33 | -43.57% | 0.00% | 0.00% | 0.42% | -6.20 | -7.34 | 1.95 | -7.01 |
| BEAT | HeartBeam, Inc. | $1.51 | 52.01M | — | — | — | — | -3.00 | 35.28 | — | -2.82 | -216.03 | 35.28 | 0.00% | — | — | -221.11% | 4079.38% | -190.60% | 0.00 | — | 1.71 | 1.47 | 0.12 | 139.00% | — | 1881.00% | -25.14% | -8.92 | 3009.64% | 0.00% | 0.00% | 0.00% | -2.81 | -3.82 | — | -22.07 |
| BIAF | bioAffinity Technologies,… | $1.06 | 4.77M | +8,873% | +321% | — | — | -0.50 | 1.73 | 0.48 | -0.59 | — | 10.68 | 36.09% | -95.63% | -96.56% | -242.44% | -270.88% | -122.70% | 0.58 | -96.82 | 0.87 | 0.72 | -0.05 | -1758.00% | 26975.00% | 2117.00% | -162.75% | -2.34 | -222.20% | 0.00% | 0.00% | 0.00% | -0.55 | -0.67 | 0.52 | -14.01 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| FGEN | FibroGen, Inc. | $9.07 | 36.69M | +230% | -59% | — | +42% | -19.49 | -4.11 | 31.31 | -6.67 | — | -4.11 | 47.47% | -507.80% | -160.63% | 22.14% | 63.58% | -14.91% | -0.32 | -18.24 | 1.47 | 0.60 | -0.16 | -8356.00% | -3671.00% | -5646.00% | -14.91% | -1.04 | 58.55% | 0.24% | -4.70% | 3.92% | -6.32 | -6.87 | 32.07 | -12.76 |
| KZR | Kezar Life Sciences, Inc. | $6.70 | 49.07M | +394% | — | — | — | -5.31 | 3.80 | — | -4.05 | — | 3.80 | 0.00% | — | — | -55.00% | -3029.25% | -45.77% | 0.14 | -56.88 | 6.76 | 6.53 | 0.32 | -1786.00% | -10000.00% | -1104.00% | -16.69% | -3.65 | -2482.15% | 0.00% | 0.00% | 2.03% | -3.63 | -4.43 | — | 4.31 |
| QNTM | Quantum BioPharma Ltd. | $3.55 | 13.64M | — | — | — | — | -0.35 | 0.46 | — | 0.08 | — | 0.80 | 0.00% | — | — | -120.69% | -212.74% | -86.23% | 0.07 | -339.16 | 1.80 | 1.65 | 0.36 | -5750.00% | — | -3649.00% | -130.92% | -1.03 | -90.66% | 0.00% | 0.00% | 52.41% | 0.07 | 0.16 | — | -16.34 |
| RNTX | Rein Therapeutics Inc. | $1.14 | 29.97M | — | — | — | — | -0.57 | 0.66 | — | -0.81 | -21.57 | 6.09 | 0.00% | — | — | -205.24% | -408.03% | -71.76% | 0.00 | — | 2.38 | 2.24 | 0.46 | 263.00% | — | 1254.00% | -62.45% | -3.88 | -143.12% | 0.00% | 0.00% | 0.00% | -0.35 | -1.02 | — | -8.63 |
| STRR | Star Equity Holdings, Inc… | $9.98 | 34.29M | +11,500% | +1,775,496% | — | +1,761% | -3.07 | 0.79 | 0.60 | -3.35 | -1.19 | 1.00 | 20.72% | -15.77% | -19.56% | -23.46% | -32.46% | -18.39% | 0.03 | — | 3.58 | 3.31 | 3.31 | 25766.00% | -6693.00% | -50185.00% | -25.05% | -0.46 | -31.00% | 6.36% | -19.50% | 7.23% | -1.92 | -2.01 | 0.30 | -8.72 |
About Inotiv, Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
- CEO
- Robert W. Leasure Jr.
- Employees
- 1.98K
- Beta
- 4.16
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.32 ÷ $0.31) − 1 = +3.23% (DCF, example).